Literature DB >> 23394095

The role of lifestyle change in the prevention and treatment of NAFLD.

Elena Centis1, Rebecca Marzocchi, Alessandro Suppini, Riccardo Dalle Grave, Nicola Villanova, Ingrid J Hickman, Giulio Marchesini.   

Abstract

Healthy habits in terms of food intake and physical activity are first-line approach to prevention and treatment of nonalcoholic fatty liver disease, but difficulties arise in turning attempts into practice. Independently of the specific role of individual nutrients, not universally proven, overweight, obesity and diabetes are the specific conditions most frequently associated with hepatic fat accumulation. Accordingly, weight loss is mandatory in the majority of patients; this can be achieved by dietary restriction, but is rarely maintained in the long-term. Physical activity programs, both aerobic and resistance exercise may improve cardiorespiratory fitness, reduce the multiple conditions associated with the metabolic syndrome and help weight loss maintenance. However, motivating sedentary individuals to move is difficult and is favored by structured programs carried out along the lines of cognitive-behavior therapy. The role of behavior therapy is now supported by pilot studies, observational studies and finally by a randomized controlled study with histological outcomes. In the future, behavior interventions might be supported by important technological advances, such as smart phone technology and webbased platforms to facilitate interactive engagement amongst patients and with their health care providers. Lifestyle programs must also incorporate methods of overcoming barriers to accessing health service, engaging with workplace health programs and linking with community attempts to improve public health.

Entities:  

Mesh:

Year:  2013        PMID: 23394095

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

Review 1.  Exercising the hepatobiliary-gut axis. The impact of physical activity performance.

Authors:  Emilio Molina-Molina; Raquel Lunardi Baccetto; David Q-H Wang; Ornella de Bari; Marcin Krawczyk; Piero Portincasa
Journal:  Eur J Clin Invest       Date:  2018-06-14       Impact factor: 4.686

Review 2.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

3.  Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte.

Authors:  Jason S Yang; Weipeng Qi; Renalison Farias-Pereira; Stephanie Choi; John M Clark; Daeyoung Kim; Yeonhwa Park
Journal:  Food Chem Toxicol       Date:  2019-02-06       Impact factor: 6.023

Review 4.  Circadian clock control of hepatic lipid metabolism: role of small heterodimer partner (Shp).

Authors:  Li Wang; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-07-29       Impact factor: 2.895

Review 5.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

6.  Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach.

Authors:  Liang Dai; Jingjuan Xu; Baocheng Liu; Yanqi Dang; Ruirui Wang; Lijie Zhuang; Dong Li; Lulu Jiao; Jianying Wang; Lei Zhang; Linda L D Zhong; Wenjun Zhou; Guang Ji
Journal:  Front Med       Date:  2022-04-26       Impact factor: 4.592

Review 7.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease.

Authors:  Mohammad J Alkhatatbeh; Lisa F Lincz; Rick F Thorne
Journal:  Exp Ther Med       Date:  2016-02-10       Impact factor: 2.447

9.  Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: a pilot trial.

Authors:  Sechang Oh; Tsuyoshi Maruyama; Kiyoshi Eguchi; Takashi Shida; Emi Arai; Tomonori Isobe; Yoshikazu Okamoto; Junichi Shoda
Journal:  Ther Clin Risk Manag       Date:  2015-03-04       Impact factor: 2.423

10.  Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014.

Authors:  Giorgio Maria Saracco; Andrea Evangelista; Sharmila Fagoonee; Giovannino Ciccone; Elisabetta Bugianesi; Gian Paolo Caviglia; Maria Lorena Abate; Mario Rizzetto; Rinaldo Pellicano; Antonina Smedile
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.